CD8A and neoplasm: Based on identified three independent prognostic indicators (CD8+ and CD20+ Immunogradient indicators and the histological feature of infiltrative tumor growth pattern), we computed CD8-CD20 Immunogradient score and immuno-interface score (IIS) for CRC which is a potential MSI status-independent prognostic tool based exclusively on TME features.